Ioanna Gioni
Late Development Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.
Journal: Future oncology (London, England)
Published: February 28, 2025
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Journal: Cancer chemotherapy and pharmacology
Published: November 27, 2020
Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
Journal: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
Published: June 02, 2015
Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.
Journal: Pharmacoepidemiology and drug safety
Published: August 08, 2014
Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
Journal: Pharmaceutical statistics
Published: June 25, 2014
Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
Journal: Pharmaceutical statistics
Published: April 09, 2014
Development and validation of a predictive mortality risk score from a European hemodialysis cohort.
Development and validation of a predictive mortality risk score from a European hemodialysis cohort.
Journal: Kidney international
Published: November 24, 2013
Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study.
Journal: BMC nephrology
Published: April 20, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026